

Review Article

Integrative Gastroenterology and Hepatology

Immunotherapy and Pancreatic Cancer

Allen T*, Shoja G and Court NB

Global Allied Pharmaceuticals, Center for Excellence in Research and Development, USA

***Correspondence:** Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and Development, 160 Vista Oak Dr. Longwood, FL 32779, USA, E-mail: timallenmed69@gmail.com

Received date: December 20, 2018; Accepted date: January 22, 2019; Published date: January 27, 2019

Abstract

Pancreatic cancer is an aggressive and highly lethal form of pancreatic malignancy which is the fourth leading cause of cancer-related deaths in men and women in the USA. According to the American Cancer Society in 2014, it was estimated that about 46,420 people (23,530 men and 22,890 women) were diagnosed of pancreatic cancer. Additionally, in the same year about 39,590 people (20,170 men and 19,420 women) died of pancreatic cancer. It is highly observed men over women and also common with increasing age. The availability of new technology in diagnosis helps in the early detection of the pancreatic cancer. These technologies will serve as the primary requirement for management of disease. The exact cause of pancreatic cancer is not known, several risk factors had been indicated leading to pancreatic cancer. Immunotherapy has been a promising development in the past few years. The recent activities have increased the understanding of the tumor microenvironment, various immunotherapeutic modalities or combination therapy (such as chemotherapy with immunotherapy) had been applied in clinical trial. Additionally, the effects of such modalities in combination with immunotherapy in cancer patients are in still exploratory phase.

Keywords: Pancreatic cancer, K-ras mutations, Cyclin-dependent kinase (CKD) Rb retinoblastoma, Protein phosphorylation, Tumorigenesis, Oncoprotein HDM2, Ductal adenocarcinoma, Pancreatic ductal cancers, Interstitial lung disease (ILD), Adoptive T cell transfer, Ligands, Kinase inhibitors, Monoclonal antibodies, Therapeutic vaccines, Adoptive T cell transfer, Adjuvant immunotherapies, Cytokines, p53 transcription factor pancreatic adenocarcinoma, Immunotherapeutic modalities

Abbreviations: CKD: Cyclin-dependent Kinase; DNA: Deoxyribose Nucleic Acid; FDA: Federal Drug Administration; ILD: Interstitial Lung Disease; MABS: Monoclonal Antibodies

Introduction

Pancreatic cancer is the fourth leading cause of cancer-related deaths in men and women in the USA [1]. Pancreatic cancer is an aggressive and highly lethal form of pancreatic malignancy [2]. Pancreatic tumors usually display ductal, acinar, or endocrine differentiation. The majority (approximately 95%) of pancreatic tumors arises from the exocrine component of the pancreas, and out of these the most common is ductal adenocarcinoma [1].

According to the American Cancer Society in 2014, it was estimated that about 46,420 people (23,530 men

and 22,890 women) were diagnosed of pancreatic cancer. Additionally, in the same year about 39,590 people (20,170 men and 19,420 women) died of pancreatic cancer. Pancreatic cancer is more common with increasing age and slightly more common in men than women. Pancreatic cancer accounts for about 3% of all the cancers in the US, and accounts for about 7% of cancer deaths. The average lifetime risk of developing pancreatic cancer is about 1 in 67 (1.5%). In 2011, there were an estimated 43,538 people living with pancreatic cancer in the United States [3].

It includes different types of histopathologic and

genetic characteristics. The availability of new technology in diagnosis helps in the early detection of the pancreatic cancer.

Etiology/Predisposing factors

The exact cause of pancreatic cancer is not known, but there are several risk factors that lead to this disease. Some of these risk factors affect the DNA of the cells of pancreas, which can result in abnormal cell growth and may lead to development of tumors [4].

Factors that increase the risk of pancreatic cancer are as follows:

Cigarette smoking: Smoking doubles the risk of developing pancreatic cancer.

Age: Pancreatic cancer increases with age. More than 80% of the cases develops in between the ages of 60-80.

Race: Pancreatic cancer is more common in the African American population than whites.

Gender: Pancreatic cancer is more common in men than in women.

Chronic pancreatitis: Long-term inflammation of the pancreas (pancreatitis) also increases the risk of developing cancer.

Diabetes: It is a symptom of pancreatic cancer, and long-standing adult-onset diabetes also increases the risk of pancreatic cancer.

Obesity: Obesity may be a risk factor that can develop pancreatic cancer.

Diet: Diet high in meats, cholesterol fried foods and nitrosamines may increase the risk, while diet high in fruits and vegetables reduces the risk of developing pancreatic cancer.

Occupation: Occupation involving exposure to carcinogens such as chlorinated hydrocarbons, formaldehyde, pesticides, organochlorines and other various substances may result in an increased risk of pancreatic cancer and contributes 5% of the overall risk.

Genetics: A number of inherited cancer syndromes increase the risk of pancreatic cancer. These include inherited mutations in the BRCA2, FAMMM, PalB2 or

Peutz-Jeghers genes.

Preexisting diseases: All types of chronic pancreatitis (alcoholic, non-alcoholic, hereditary, tropical) have been linked to the subsequent development of pancreatic cancer.

Pathophysiology and molecular basis

More than 85% of pancreatic ductal cancers have an activating point mutation in the K-ras gene at a very early stage of pancreatic-cancer development [5]. The detection of K-ras mutations in the duodenal juice, pancreatic juice, and in the stool of patients with pancreatic cancer has been proposed as an early detection strategy [6,7]. p16, which is a cyclin-dependent kinase (CKD) inhibitor, is altered in up to 85% of pancreatic cancer, resulting in cell cycle progression through Rb retinoblastoma protein phosphorylation [8] in table 1.

Table 1: Commonly altered oncogenes in pancreatic adenocarcinoma [9,10].

Oncogenes	Location of chromosomes
K-ras	12p
HER2/neu	17q
AKT2	19q
MYB	6q

The second most frequently inactivated tumor-suppressor gene is TP53, a well-characterized tumor-suppressor located on chromosome 17p. Its inactivation is a late event in tumorigenesis. The p53 transcription factor is normally maintained at very low level as a result of interaction with the oncoprotein HDM2 (the human homologue of MDM2), which targets p53 for proteosomal degradation. Under conditions of cellular stress, such as genotoxic damage or oncogene activation, the HDM2-p53 interaction is inhibited, and the p53 protein is stabilized. The levels of p53 thus, increases and it regulates a transcription response leading to cell cycle arrest or to apoptosis. After Oncogene-mediated activation, p14ARF protein inhibits MDM2, leading to the stabilization and thus activation of p53.

The MADH4 gene (DPC4 or SMAD4) is inactivated in 55% of pancreatic adenocarcinomas [11]. Like TP53, MADH4 inactivation is a late event in pancreatic tumorigenesis [12-16]. Rozenblum and colleagues noticed that [17], in the comprehensive mutational analysis of pancreatic ductal cancer, all tumors harbor mutations in the K-ras Oncogene. The individual mutational frequencies of

tumor-suppressor genes include: p16, TP53, MADH4, and BRCA2 were 82%, 76%, 53%, and 10%, respectively [18] (Table 2).

Table 2: Commonly altered tumor suppressor genes in pancreatic adenocarcinoma [9,10].

Tumour-suppressor and genome maintenance genes	Location of chromosomes
TP53	17p
CDKN2A*	9p
CDKN2A†	9p
CDKN2B	9p
MADH4	18q
FHIT	3p
RBI	13q
BRCA2	13q
STK11	19q
MAP2K4	17p
ALK5	9q
TGFBR2	3p
TGFBR2§	3p
MLH1	3p

Targeted Therapy

The targeted therapy modalities under clinical investigation for pancreatic cancer are divided into 6 main categories: kinase inhibitors, monoclonal antibodies, therapeutic vaccines, adoptive T cell transfer, adjuvant immunotherapies, and cytokines.

Kinase inhibitors

FDA approved kinase inhibitors

Erlotinib [19]

Indications and use: Erlotinib is a kinase inhibitor and has been received FDA approval for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.

Contraindications: It is contraindicated in patients with hypersensitivity.

Warnings: It has no black box warning. Common warnings are Interstitial Lung Disease (ILD)-like events, acute renal failure, hepatic failure and hepato-renal syndrome, gastrointestinal perforations.

Adverse Events: The most common adverse reactions (>50%) in pancreatic cancer are fatigue, rash, nausea and anorexia.

Non-FDA approved kinase inhibitors (Table 3) Monoclonal Antibodies

Monoclonal antibodies (MABs) target specific antigens on tumors. Several MABs are currently being tested in clinical trials:

Non-FDA approved monoclonal antibodies (Table 4)

Bevacizumab: Bevacizumab is a humanized anti-Vascular endothelial growth factor (VEGFO) monoclonal IgG1 antibody approved by the U.S. Food and Drug Administration (FDA) for second-line treatment of advanced glioblastoma multiform as single line treatment and in combination with chemotherapy, it is approved for the treatment of advanced colorectal cancer (CRC), advanced non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC),

Cetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor and a recombinant chimeric monoclonal antibody, which has been successfully used in the treatment of the Non-small cell lung cancer, colorectal cancers and squamous cell skin cancer (Non-FDA approved).

Trastuzumab: Trastuzumab is registered for the treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, for adjuvant treatment of localized HER-2+ breast cancer, and for HER-2+ metastatic adenocarcinoma of the stomach or gastroesophageal junction.

Demcizumab: It is a humanized monoclonal antibody which blocks Delta-like ligand 4 (DLL4), a ligand of Notch receptors. Notch signaling has been implicated as a key signaling pathway in cancer stem cells. By treating patients with a combination of Demcizumab and a cytotoxic chemotherapy.

Vantictumab: Vantictumabis a human IgG2 monoclonal antibody designed for the treatment of cancer by inhibiting 'wntsignalling pathways' by targeting the frizzled receptors on cancer cells.

Table 3: Non-FDA approved kinase inhibitors [20-31].

Kinase inhibitors	Clinical trial identifier no.	Phase	Study design	Target
Ruxolitinib	NCT02117479	Phase III	Randomized, Double blind	JAK
X-82	NCT01784861	Phase I/II	Non-Randomized, Safety/Efficacy Study, open label	VEGFR
Dinaciclib	NCT01783171	Phase I	Randomized, Safety/Efficacy Study, open label	Cyclin dependent kinase
Sphingosine kinase-2 inhibitor ABC294640	NCT01488513	Phase I	Safety Study, open label	SK2
Sorafenib	NCT00541021	Phase III	Randomized, Double blind	RAF kinase
Trametinib	NCT02079740	Phase I, Phase II	Safety/Efficacy Study, open label	MEK MAPK/ERK kinase
Vandetanib	NCT01601808	Phase II	Randomized, Safety/Efficacy Study, Double blind	VEGFR2
Dasatinib	NCT01652976	Phase II	Safety/Efficacy Study, open label	Tyrosine kinase
Regorafenib	NCT02080260	Phase II	Efficacy Study, open label	VEGFR 2 and 3, and Ret, Kit, PDGFR and Raf kinases
Cabozantinib	NCT01663272	Phase I	Safety Study, open label	RTKs
Alisertib	NCT01924260	Phase I	Safety Study, open label	Aurora K kinase
Momelotinib	NCT02244489	Phase I	Non-Randomized, Safety Study, open label	JAK1/2

Table 4: Non-FDA approved monoclonal antibodies [32-42].

mAbs	Clinical trial identifier no.	Phase	Study design	Target
Bevacizumab	NCT00088894	Phase III	Randomized, Safety/Efficacy Study, double blind	VEGF
Cetuximab	NCT00871169	Phase II	Efficacy Study, open label	EGFR
OMP-59R5	NCT01647828	Phase I/II	Randomized, Safety/Efficacy Study, double blind	Cancer stem cell
IMMU-132	NCT01631552	Phase I, Phase II	Safety/Efficacy Study, open label	Trop-2
MM-151	NCT01520389	Phase I	Non-Randomized, Safety Study, open label	EGFR
IMMU-107	NCT01956812	Phase III	Randomized, Efficacy Study, Double blind	MUC1 antigen
Trastuzumab	NCT00923299	Phase I/II,	Non-Randomized, open label	HER2
NPC-1C/NEO-102	NCT01040000	Phase I, Phase II	Safety/Efficacy Study, open label	CPAAs
MLN0264	NCT02202785	Phase II	Efficacy Study, open label	GCC
Demcizumab	NCT01189929	Phase I	Non-Randomized, Safety/Efficacy Study, open label	DLL4
Vantictumab	NCT02005315	Phase I	Non-Randomized, Safety/Efficacy Study, open label	CSC

Vaccine based immunotherapy

Several trials of vaccines, given alone or with other therapies, are currently enrolling patients with pancreatic cancer.

Non-FDA approved Vaccines (Table 5)

Adoptive cell therapy

Another major opportunity of immunotherapy for pancreatic cancer is adoptive T cell transfer. Several trials of adoptive T cell transfer techniques are currently on the way for patients with pancreatic cancer, including:

Non-FDA approved adoptive T cell therapy (Table 6)

Adjuvant immunotherapies

Adjuvants are used alone or in combination with other immunotherapy. Some adjuvant immunotherapy use ligands. These ligands may be stimulating (agonists) or blocking (antagonists).

Non-FDA approved adjuvant therapy (Table 7)

Cytokines

Cytokines are messenger molecules that help control the growth and activity of immune system cells.

Non-FDA approved cytokines (Table 8)

Checkpoint inhibitors

Non-FDA approved checkpoint inhibitors (Table 9)

Conclusion

There is a strong rise in immunotherapy options for resilient cancers like pancreatic adenocarcinoma. Our success in treating pancreatic cancer is increasing and advancing with the knowledge of the function of the immune system. Immunotherapy has been a promising development in the past few years. The recent activities have increased our understanding of the tumor microenvironment, various immunotherapeutic modalities or combination therapy (like chemotherapy with immunotherapy). Additionally, the effects of such modalities in combination with immunotherapy in cancer patients are still exploratory phase. The complete perspective of immunotherapy treatment has not been realized and utilized. Proper preclinical and clinical designs are the important pillars in understanding the future of immunotherapy in treating cancer patients.

Table 5: Non-FDA approved vaccines [43-49].

Drug	Clinical trial identifier no.	Phase	Study design	Target
Algenpantucel-L	NCT01836432	Phase III	Randomized, Safety/Efficacy Study, open label	Block tumor growth
GVAX	NCT02004262	Phase II	Randomized, Safety/Efficacy Study, open label	Block tumor growth
NY-ESO-1 reactive TCR	NCT01697527	Phase II	Safety/Efficacy Study, open label	NY-ESO-1
DCVax	NCT01882946	Phase I, Phase II	Safety/Efficacy Study, open label	Reduce tumor growth
DEC-205-NY-ESO-1 fusion protein vaccine	NCT01522820	Phase I	Non-Randomized, Safety Study, open label	NY-ESO-1 (cancer testis antigen)
Survivin peptide vaccine	NCT00108875	Phase I, Phase II	Non-Randomized, Safety/Efficacy Study, open label	T cell
Autologous gp96 vaccination	NCT02133079	Phase I, Phase II	Safety/Efficacy Study, open label	T cell
PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine	NCT01088789	Phase II	Randomized, open label	GM-CSF

Table 6: Non-FDA approved adoptive T cell therapy [50-55].

Drug	Clinical trial identifier no.	Phase	Study design	Target
CAR T cells	NCT01583686	Phase I/II,	Non-Randomized, Safety/Efficacy Study, open label	Mesothelin
TIL	NCT01174121	Phase II	Non-Randomized, Safety/Efficacy Study, open label	Cancer cells
Anti-NY ESO-1 mTCR PBL	NCT01967823	Phase II	Non-Randomized, Safety/Efficacy Study, open label	NY-ESO-1
Anti-MAGE-A3-DP4 TCR	NCT02111850	Phase I/II	Non-Randomized, Safety/Efficacy Study, open label	MAGE-A3-DP4
CAR T cells	NCT01218867	Phase I, Phase II	Non-Randomized, Safety/Efficacy Study, open label	VEGFR2
NY-ESO-1 reactive TCR	NCT01697527	Phase II	Safety/Efficacy Study, open label	NY-ESO-1

Table 7: Non-FDA approved adjuvant therapy [56].

Drug	Clinical trial identifier no.	Phase	Study Design	Target
Entolimod	NCT01527136	Phase I	Safety Study, open label	Block tumor growth

Table 8: Non-FDA approved cytokines [57].

Drug	Clinical trial identifier no.	Phase	Study design	Target
AM0010	NCT02009449	Phase I	Non-Randomized, Safety Study, open label	Block tumor growth

Table 9: Non-FDA approved checkpoint inhibitors [58-61].

Drug	Clinical trial identifier no.	Phase	Study design	Target
Ipilimumab	NCT01473940	Phase I	Safety study, open label	Block tumor growth
MEDI4736	NCT01693562	Phase I, Phase II	Non-Randomized, Safety/Efficacy Study, open label	PD-L1
Nivolumab or Nivolumab + Ipilimumab	NCT01928394	Phase I, Phase II	Randomized, Efficacy Study, open label	Block tumor growth
Pembrolizumab	NCT02305186	Phase I, Phase II	Randomized, Safety/Efficacy Study, open label	PD-1

References

- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA: A Cancer Journal for Clinicians*. 2010;60(5):277-300. doi: <https://dx.doi.org/10.3322/caac.20073>
- Hidalgo M. Pancreatic cancer. *N Engl J Med*. 2010;362(17):1605-1617. doi: <https://dx.doi.org/10.1056/NEJMra0901557>
- Pancreatic cancer. American cancer society. <https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html>
- Causes of pancreatic cancer. Johns Hopkins Int Gast Hepatol, 2(1): 106-114 (2019)
- medicine. <http://pathology.jhu.edu/pc/BasicCauses.php?area=b>.
- Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell*. 1988;53(4):549-554.
- Wenger FA, Zieren J, Peter FJ, Jacobi CA, Müller JM. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. *Langenbecks Arch Surg*. 1999;384(2):181-186.
- Uehara H, Nakaizumi A, Tatsuta M, et al. Diagnosis of pancreatic cancer by detecting telomerase activity

- in pancreatic juice: comparison with K-ras mutations. *Am J Gastroenterol*. 1999;94(9):2513-2518. doi: <https://dx.doi.org/10.1111/j.1572-0241.1999.01386.x>
8. Koliopanos A, Friess H, Ozawa F, Kleeff J, Büchler M. The molecular basis of pancreatic cancer. *Ann Gastroenterol*. 2000;13(3):188-195.
 9. King TC. Molecular pathobiology of pancreatic adenocarcinoma. *Frontiers in Bioscience*. 1998;3(4):d1148-1160. doi: <https://dx.doi.org/10.2741/A351>
 10. Sohn TA, Yeo CJ. The molecular genetics of pancreatic ductal carcinoma: *Surgical Oncology*. 2000;9(3):95-101. doi: [https://dx.doi.org/10.1016/S0960-7404\(00\)00041-4](https://dx.doi.org/10.1016/S0960-7404(00)00041-4)
 11. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science*. 1996;271(5247):350-353. <https://www.ncbi.nlm.nih.gov/pubmed/8553070>
 12. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. *Cancer Res*. 1998;58(11):2339-2342. <https://www.ncbi.nlm.nih.gov/pubmed/9622070>
 13. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. *Am J Pathol*. 1999;154(6):1835-1840. doi: [https://dx.doi.org/10.1016/S0002-9440\(10\)65440-5](https://dx.doi.org/10.1016/S0002-9440(10)65440-5)
 14. Ozçelik H, Schmocker B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. *Nat Genet*. 1997;16(1):17-18. doi: <https://dx.doi.org/10.1038/ng0597-17>
 15. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. *Cancer Res*. 1996;56(23):5360-5364. <https://www.ncbi.nlm.nih.gov/pubmed/8968085>
 16. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. *Am J Pathol*. 2000;156(5):1767-1771. doi: [https://dx.doi.org/10.1016/S0002-9440\(10\)65047-X](https://dx.doi.org/10.1016/S0002-9440(10)65047-X)
 17. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. *Cancer Res*. 1997;57(9):1731-1734. <https://www.ncbi.nlm.nih.gov/pubmed/9135016>
 18. Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. *Int J Cancer*. 2001;92(3):361-369. <https://www.ncbi.nlm.nih.gov/pubmed/11291072>
 19. FDA approved label TARCEVA® (Erlotinib). Manufactured by Schwarz Pharma Manufacturing. Last updated on 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf.
 20. Incyte Corporation. Study of ruxolitinib in pancreatic cancer patients (Janus 1). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 FEB 15. <https://clinicaltrials.gov/ct2/show/NCT02117479>.
 21. Washington University School of Medicine. VEGFR/PDGFR Dual kinase inhibitor X-82 and everolimus for treating patients with pancreatic neuroendocrine tumors. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Feb 15. <https://clinicaltrials.gov/ct2/show/NCT01784861..>
 22. National Cancer Institute (NCI). Dinaciclib and akt inhibitor mk2206 in treating patients with pancreatic cancer that cannot be removed by surgery. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Feb 15. <https://clinicaltrials.gov/ct2/show/NCT01783171>.
 23. Medical University of South Carolina. ABC294640 in treating patients with advanced solid tumors (ABC-101). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Feb 15. <https://clinicaltrials.gov/ct2/show/NCT01488513>.
 24. Institut Paoli-Calmettes; National Cancer Institute (NCI). Gemcitabine with or without sorafenib in treating patients with locally advanced or metastatic pancreatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 25. National Cancer Institute (NCI). Trametinib and navitoclax in treating patients with advanced or metastatic solid tumors. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 26. University of Liverpool; Dr Gary Middleton, University of Liverpool. Clinical trial comparing gemcitabine and vandetanib therapy with gemcitabine alone in pancreatic carcinoma (vip). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 27. University of Florida. Phase II Study of 5-FU, oxaliplatin plus dasatinib in metastatic pancreatic

- adenocarcinoma (folfox-d). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
28. Stuart Salmon, Carolinas Healthcare System. A Study of regorafenib in advanced pancreatic cancer patients. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 29. University of Michigan Cancer Center. A trial of cabozantinib (xl184) and gemcitabine in advanced pancreatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 30. University of California, Davis. Alisertib and gemcitabine hydrochloride in treating patients with solid tumors or pancreatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 31. Gilead Sciences. Momelotinib combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15. .
 32. National Cancer Institute (NCI). Gemcitabine with or without bevacizumab in treating patients with locally advanced or metastatic pancreatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15. <https://clinicaltrials.gov/ct2/show/NCT00088894>.
 33. New Mexico Cancer Care Alliance. Combination of irinotecan, oxaliplatin and cetuximab for locally advanced or metastatic pancreatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15. . <https://clinicaltrials.gov/ct2/show/NCT00871169>.
 34. OncoMed Pharmaceuticals, Inc.; A Phase 1b/2 study of omp-59r5 in combination with nab-paclitaxel and gemcitabine in subjects with previously untreated stage iv pancreatic cancer (ALPINE). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15. <https://clinicaltrials.gov/ct2/show/NCT01647828>.
 35. Immunomedics, Inc.; Phase I/II study of immu-132 in patients with epithelial cancers. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15. <https://clinicaltrials.gov/ct2/show/NCT01631552>.
 36. Merrimack Pharmaceuticals; Safety study of the drug mm-151 in patients with advanced solid tumors resisting ordinary treatment. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15. <https://clinicaltrials.gov/ct2/show/NCT01520389>.
 37. Immunomedics, Inc.; Phase 3 trial of 90Y-clivatuzumab tetraxetan & gemcitabine vs placebo & gemcitabine in metastatic pancreatic cancer (PANCRIT@-1). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15. .
 38. Institut du Cancer de Montpellier - Val d'Aurelle; National Cancer Institute (NCI). Cetuximab and trastuzumab in treating patients with metastatic pancreatic cancer that progressed after previous treatment with gemcitabine. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 39. Precision Biologics, Inc; Phase 2 study of NPC-1C chimeric monoclonal antibody to treat pancreatic and colorectal cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 40. Millennium Pharmaceuticals, Inc.; A study of mln0264 in patients with pancreatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 41. OncoMed Pharmaceuticals, Inc.; A study of gemcitabine and demcizumab (OMP-21M18) with or without abraxane® as 1st-line treatment in subjects with locally advanced or metastatic pancreatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 42. OncoMed Pharmaceuticals, Inc.; A study of vantictumab (OMP-18R5) in combination with Nab-Paclitaxel and gemcitabine in previously untreated stage IV pancreatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 43. NewLink Genetics Corporation; Immunotherapy study in borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 44. Aduro BioTech, Inc.; Safety and efficacy of combination Listeria/GVAX pancreas vaccine in the pancreatic cancer setting (ECLIPSE). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 45. Northwest Biotherapeutics; Safety and efficacy study of DCVax-direct in solid tumors. In: *ClinicalTrials.gov*

- gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
46. Roswell Park Cancer Institute; Vaccine therapy with or without sirolimus in treating patients with ny-eso-1 expressing solid tumors. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 47. Julius-Maximilians University; survivin peptide vaccination for patients with advanced melanoma, pancreatic, colon and cervical cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 48. Cure&Sure Biotech Co., LTD; Immunotherapy of tumor with autologous tumor derived heat shock protein gp96. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 49. Sidney Kimmel Comprehensive Cancer Center; A trial of boost vaccinations of pancreatic tumor cell vaccine. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.
 50. National Cancer Institute (NCI); CAR T cell receptor immunotherapy targeting mesothelin for patients with metastatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 51. National Cancer Institute (NCI); Immunotherapy using tumor infiltrating lymphocytes for patients with metastatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 52. National Cancer Institute (NCI); T cell receptor immunotherapy targeting NY-ESO-1 for patients with NY-ESO-1 expressing cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 53. National Cancer Institute (NCI); T cell receptor immunotherapy targeting MAGE-A3 for patients with metastatic cancer who are HLA-DP0401 positive. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 54. National Cancer Institute (NCI); CAR T cell receptor immunotherapy targeting VEGFR2 for patients with metastatic cancer. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 55. Jonsson Comprehensive Cancer Center; Gene and vaccine therapy in treating patients with advanced malignancies. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 56. National Cancer Institute (NCI); Roswell Park Cancer Institute. Entolimod in treating patients with locally advanced or metastatic solid tumors that cannot be removed by surgery. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 57. ARMO BioSciences; A Phase 1 Study of AM0010 in patients with advanced solid tumors. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 58. Northwestern University; Mary Mulcahy, Northwestern University. Ipilimumab and gemcitabine hydrochloride in treating patients with stage III-IV or recurrent pancreatic cancer that cannot be removed by surgery. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 59. MedImmune LLC; A Phase ½ study to evaluate MEDI4736. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 60. Bristol-Myers Squibb; Bristol-Myers Squibb. A Phase ½, open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 15.
 61. Osama Rahma, MD; Osama Rahma, MD, University of Virginia. Safety and immunological effect of pembrolizumab in resectable or borderline resectable pancreatic cancer (UVA-PC-PD101). In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 April 15.